Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 3,969–3,976 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) TAK-609 Hunter Syndrome NDA Filing Ongoing Intrathecal Genetic Disorder
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) Soticlestat (TAK-935/OV935)- (Skyline) Dravet Syndrome / Lennox-Gastaut Syndrome Phase 3 Data Released Oral Neurology
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) Soticlestat (TAK-935/OV935)- (Skyline) Dravet Syndrome / Lennox-Gastaut Syndrome Phase 3 Data Released Oral Neurology
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) Elritercept (KER-050) Myelodysplastic syndromes (MDS) Phase 3 Trial Planned Subcutaneous Hematology
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) Modakafusp alfa (TAK-573) Relapsed/Refractory Multiple Myeloma Phase 3 Trial Planned Intravenous Oncology
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) Pevonedistat-3001 - (PANTHER) Higher-risk myelodysplastic syndromes (HR-MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia (AML) Phase 3 Trial Discontinued Intravenous Hematology
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) Ixazomib - (TOURMALINE-MM4) Multiple myeloma Phase 3 Trial Discontinued Oral Oncology
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) NINLARO (ixazomib) lenalidomide and dexamethasone - TOURMALINE-MM2 Multiple myeloma Phase 3 Trial Discontinued Oral Oncology
1…495496497498499…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.